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Received September 1, 2011; accepted February 10, 2012AbstractBackground: Circulatory assist devices are applied to support patients with end-stage heart failure or circulatory collapse. Extracorporeal
membrane oxygenation (ECMO) and ventricular assist device (VAD) are the two devices that are commonly used in these situations. However,
in patients undergoing ECMO, complications occur more frequently and are more severe than in those with VAD, especially in patients with
coagulopathy. The cause of coagulopathy is seldom reported; therefore, the current prospective study was designed to compare the coagulation
status between patients who received ECMO and bridged VAD thereafter.
Methods: The cases for our study were collected between December 2005 and January 2010. A total of 21 patients with VAD were enrolled.
Seven patients received initial ECMO support and were subsequently shifted to VAD. Use of blood transfusion products by patients was recorded
during application of ECMO and VAD. Thrombelastography (TEG) was performed pre-ECMO and pre-VAD, and thereafter to 1 week post-VAD
implantation. The relevant parameters that were examined included coagulation time (R: resting, K: kinetics, seconds), angle (a, degrees),
maximal amplitude (MA, mm), clot strength (G, dynes/cm2), and estimated percent lysis in 30 minutes (LY30, %). Coagulation status and
average unit per day of blood transfusion at pre-VAD and post-VAD status were recorded. TEGs of pre-VAD and post-VAD implantation were
compared in order to determine the frequency of bleeding.
Results: Average results from seven cases were incorporated into the current analysis. The patient transfusion requirement was reduced after
implantation of the VAD. The TEG of post-VAD implantation was improved from the earlier pre-VAD results (ECMO status). Ultimately, TEG
resulted in significant differences in R, K, angle, MA, and G, postoperatively.
Conclusion: Coagulopathy of patients with VAD improved after bridging from ECMO, which can be attributed to improved coagulation factor
and platelet function. Thus, bleeding complications are reduced.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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In the last 20 years, the use of circulatory assist devices
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http://dx.doi.org/10.1016/j.jcma.2012.06.004support patients with end-stage heart failure or circulatory
collapse. Two commonly used devices are the extracorporeal
membrane oxygenation (ECMO) unit and the ventricular
assist device (VAD). ECMO supports cardiopulmonary
function, including hemodynamic stability and gas
exchange, and can be implemented rapidly and with ease.
Hence, it was widely used in the event of acute cardiopul-
monary collapse. However, certain complications can arisehinese Medical Association. All rights reserved.
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coagulopathy.
VAD is well suited to bridge a patient with end-stage heart
disease until heart transplantation (bridge to heart trans-
plantation) or recovery (bridge to recovery).1 Complications
associated with VAD use can include bleeding and thrombo-
embolism.2 However, blood transfusions in patient post-VAD
implantation are required less frequently than those in
patients using an ECMO device.
Although both of these devices provide support following
circulatory collapse, the ECMO device can be implemented at
a faster rate than VAD. Consequently, the ECMO device is
frequently used in patients with acute hemodynamic deterio-
ration. It can then be replaced with a VAD in cases that require
extended device support.
In general, thrombelastography (TEG) has firmly estab-
lished that coagulation status differs in patients using ECMO
and VAD devices.3 Therefore, the current study used TEG to
monitor continuously coagulation status in patients as they
transitioned from ECMO to VAD, because TEG is able to
better determine the improvement during coagulation.Fig. 1. TEG.2. Methods
This study was carried out prospectively after getting
study consent forms. Study cases were collected between
December 2005 and January 2010 at our medical center, and
a total of 21 patients with VAD were enrolled. Seven patients
initially received ECMO support and were subsequently
shifted to VAD. Gender, age, and diagnosis of patients were
recorded, and each patient received VeA mode ECMO
insertion from the right or left femoral vessel. In less than
1 week, use of ECMO was discontinued and patients were
shifted to VAD. After the VAD was implemented, an anti-
coagulant protocol was followed. If the patient received the
VAD of Levitronix, heparin infusion was started if the chest
tubes transported less than 50 cc/h every 2e3 hours. Acti-
vated coagulation time (ACT) was kept between 160 and 180
seconds. Four days after VAD was initiated, activated partial
thromboplastin time (APTT) was maintained at 1.3e1.6
times the normal range, and an antiplatelet aggregation agent
was added (aspirin 81e325 mg/d). Pump flow was retained at
approximately 4e5 LPM, with a speed of 3000e4000 RPM.
If the case involved a Berlin heart setup, heparin infusion was
initiated at 12e24 hours postoperatively if bleeding was
controlled (<50 mL/h) and platelet count was more than
80,000/mL. APTT was at approximately 50e60 seconds on
Postoperative Day 1, and 60e80 seconds for 2 days post-
operatively if the platelet count was more than 100,000/mL.
Dipyridamole 150 mg once per day was administered at
Postoperative Day 2, and aspirin 50 mg twice per day was
added at Postoperative Day 4. A vitamin K antagonist was
taken orally if enteral feeding was possible. The International
Normalized Ratio was maintained between 3.0 and 3.5.
Complications associated with study admission were
documented.The number of blood transfusions for each patient was
recorded during ECMO and VAD. Blood products included
fresh frozen plasma (FFP), cryoprecipitate, and platelet.
Coagulation data stayed within a predetermined range: Hct
>30 or Hb >10, and platelet number >50,000/mm.4 The
blood products were infused and the data were corrected
according to the normal range. Total blood products were
evaluated during ECMO and VAD to understand each patient’s
bleeding tendency further.
TEG was used to examine patient coagulation profile,
beginning with initiation of ECMO until 1 week post-VAD
implantation. Meanwhile, pre-ECMO TEG was also docu-
mented to determine the baseline coagulation status of each
patient. Parameters of this documentation included coagula-
tion time (R: resting time, K: kinetics, seconds), maximal
amplitude (MA, mm), angle (degrees), clot strength
(G, dynes/cm2), and estimated percent lysis in 30 minutes
(LY30, %).
Different factors are involved in the process of coagulation,
including clotting time, kinetics, strength, and lysis.5 The TEG
graphic presentation included clot formation and subsequent
lysis, and whole blood coagulation was assessed under low
shear conditions. Blood was injected into a heated cup
(<37C). A suspended pin with a wire connected to a detector
was inserted into the cup; the result was recorded by the
detector under pin movement. The cup and pin were rotated at
an angle of 4450 every 10 seconds, and, when a fibrin clot
occurred, the pin of the cup with the fibrineplatelet complex
rotated with the cuvette. The graph curve increased until
maximal clot firmness occurred and decreased when lysis was
observed.
In the TEG graph (Fig. 1), R represents resting time, K is
kinetics time, a is angle, MA is maximal amplitude, G is clot
strength (kd/sc), and LY30 is percentage of lysis during an
interval of 30 minutes. Each value of the TEG parameter of
ECMO and VAD was compared with pre-ECMO values. The
final ECMO value obtained was considered as the ECMO-
related coagulopathy total. After VAD setup was completed,
TEG was used to compare with ECMO coagulation status, to
determine any change in coagulation.
The TEG examination was self-pay, and patients signed
a consent form approved by our medical center prior to their
participation in the study.
Table 1
Circulatory assist device of patients in the study.
Gender Age Diagnosis ECMO mode ECMO duration (d) VAD mode VAD company Complication
Case 1 F 32 CHF VeA 6 V: LA (PV)
A: aorta
Levitronix ECMO wound oozing
Case 2 M 55 CAD with cardiogenic shock VeA 3 V: LA (PV)
A: aorta
Levitronix UGI bleeding
ECMO wound oozing
Case 3 M 48 ICM VeA 5 V: LA (PV)
A: aorta
Levitronix Skin ecchymosis
Case 4 F 12 Myocarditis VeA 7 V: LA (PV)
A: aorta
Levitronix No
Case 5 M 3 DCM VeA 6 V: LV (apex)
A: aorta
Berlin heart No
Case 6 M 54 ICM VeA 7 V: LV (apex)
A: aorta
Berlin heart ECMO wound oozing
Case 7 F 53 DCM VeA 4 V: LA (PV)
A: aorta
Levitronix Hematuria
Apex ¼ apical cannulation; CAD ¼ coronary artery disease; CHF ¼ chronic heart failure; DCM ¼ dilated cardiomyopathy; ECMO ¼ extracorporeal membrane
oxygenation; ICM ¼ ischemic cardiac myopathy; LA ¼ left atrium; PV ¼ pulmonary vein cannulation; UGI ¼ upper gastrointestinal; VAD ¼ ventricular assist
device.
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Daily blood transfusion product.
FFP (U/day) Cryoprecipitate
(U/day)
Platelet (U/day)a
ECMO VAD ECMO VAD ECMO VAD
Case 1 1.00 0.29 2.00 0.00 1.00 0.00
Case 2 2.00 0.57 6.00 1.14 1.33 0.29
Case 3 1.20 0.29 2.00 0.00 1.20 0.29
Case 4 0.57 0.00 1.71 0.00 1.14 0.29
Case 5 1.00 0.00 2.00 0.00 1.33 0.00
Case 6 1.14 0.57 1.71 0.00 0.86 0.00
Case 7 1.00 0.00 2.00 0.00 1.00 0.00
p 0.001 0.001 0.001
ECMO ¼ extracorporeal membrane oxygenation; FFP ¼ fresh frozen plasma;
VAD ¼ ventricular assist device.
a Platelet: pheresis.The data were analyzed by SPSS statistical software (IBM,
Version 18.0). Continuous variables are expressed as median
(minimum value e maximum value) and were compared
between ECMO status and VAD setup over the course of 7
days using the Wilcoxon rank sum test. A p value of <0.05
was considered statistically significant.
3. Results
Seven patients (four men and three women) were eligible
for study inclusion. Median participant age was 48 years
(range: 3e55 years). Two participants were diagnosed with
dilated cardiomyopathy(DCM), two with ischemic cardiac
myopathy (ICM), one with chronic heart failure (CHF), and
one with myocarditis; one was in unstable condition due to
coronary artery disease (CAD) with cardiogenic shock. All
uses of ECMO employed a venousearterial configuration with
femoral cannulation. The ECMO status was less than 1 week
in duration for each case prior to shifting over to VAD. Five
patients received Levitronix VAD. Left atrium venous
drainage was cannulated from the right upper pulmonary vein,
and the arterial tip was cannulated at the ascending aorta. Two
patients received the Berlin heart VAD. Left ventricle (LV)
venous drainage was from apical cannulation and the arterial
tip fixation was at the ascending aorta.
Two patients did not suffer from coagulopathy-related
complications, such as gastrointestinal (GI) bleeding, wound
oozing, or ecchymosis. Three patients suffered from ECMO
wound oozing and received medical reintervention to address
the bleeding. One presented with upper GI bleeding and one
with hematuria that was under medical treatment during
ECMO. One patient presented with skin ecchymosis and
observation was suggested after VAD setup (Table 1).
Due to blood component consumption and anticoagulant
agent use, a tendency bleeding was noted in patients. All seven
cases received blood product transfusions according to thecriteria and clinical requirements to maintain the balance of
coagulation. Each ECMO case received, at a minimum, FFP (4
U), cryoprecipitate (10 U), and platelet pheresis (4 U). During
the 1 week of VAD, daily averages for each individual of the
maximal requirement in FFP, cryoprecipitate, and platelet
pheresis were only 2, 8, and 2 U, respectively. A significant
reduction of blood transfusions was noted during VAD use as
compared with ECMO use (Table 2).
The TEG document included R, K, angle, MA, G, and
LY30. Prior to ECMO and VAD, ECMO status was recorded
(Table 3). Measured variables during VAD were similar to
ECMO status in individual patients.
In order to compare the overall change in each patient,
a preoperative/postoperative ratio was calculated (Table 2). On
average, the R and K values were predominantly under 1.00;
however, the MA, angle, and G were greater than 1.00. Gener-
ally, in patients with VAD, R and K times were shorter, whereas
MA, angle, andGwere greater, as compared with ECMO status.
The results of TEG from pre-ECMO, ECMO status (pre-
VAD), and VAD during the targeted 1 week were documented.
Generally, the seven cases revealed normal median TEG at
pre-ECMO, including a median R value of 5.20 minutes
Table 3
TEG in pre-ECMO and pre-VAD.
Pre-ECMO Pre-VADa p
R (4e8 min) 5.20 (2.30e7.20) 11.30 (8.10e54.20) 0.001
K (1e4 min) 2.20 (1.3e3.2) 5.20 (2.30e27.70) 0.001
MA (55e73 mm) 70.90 (64.10e78.30) 41.00 (34.60e69.00) 0.001
Angle (47e74) 69.80 (66.90e78.00) 38.8 (27.10e62.50) 0.001
G (6Ke13.2K kd/sc) 11,022.30 (7880.90e14,507.70) 3191.50 (2131.70e11,133.10) 0.001
LY30 (0e3%) 3.50 (1.00e7.60) 0.30 (0e0.90) 0.001
ECMO ¼ extracorporeal membrane oxygenation; G ¼ clot strength; K ¼ kinetics time; LY30 ¼ estimated percent lysis in 30 minutes; MA ¼ maximal amplitude;
R ¼ resting time; TEG ¼ thrombelastography; VAD ¼ ventricular assist device.
a Pre-VAD: the last day of ECMO status.
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minutes (normal range: 1e4 minutes), a median MA value of
70.90 mm (normal range: 55e73 mm), a median angle value
of 69.80 (normal range: 47e74), a median G value of
11,022.30 kd/sc (normal range: 6Ke13.2K kd/sc), and
a median LY30 of 3.50% (normal range: 0e3%) (Table 3).
After ECMO setup was completed (ECMO status), follow-up
TEG occurred until pre-VAD. The median TEG of pre-VAD at
Day 1 (ECMO status) was documented. Median R was 11.30
minutes, K 5.20 minutes, MA 41.00 mm, angle 38.80, G
3191.50 kd/sc, and LY30 0.30%. The significant difference of
TEG change was found from the pre-ECMO to ECMO status.
The ECMO shift to VAD occurred after 1 week, at which
time additional TEG follow-up was performed. The value of R
decreased to a median of 12.10 minutes at VAD Day 1 from
11.30 minutes at ECMO status. Median reported values were
8.90, 11.50, 9.50, 9.10, 10.90, and 9.40 minutes at VAD Days
2, 3, 4, 5, 6, and 7, respectively (Fig. 2A).
The K value decreased to a median of 3.60 minutes at VAD
Day 1 from 5.20 minutes at ECMO status. At VAD Days 2, 3,
4, 5, 6 and 7, median values were 3.00, 5.50, 3.70, 2.70, 3.40,
and 2.90 minutes, respectively, for each individual (Fig. 2B).
The MA value increased to a median of 54.10 mm at VAD
Day 1. At VAD Days 2, 3, 4, 5, 6, and 7, the reported values
were 58.40, 56.30, 60.10, 61.10, 61.20, and 64.90 mm,
respectively, for each individual (Fig. 2C).
The angle was found to be similar to MA. The value
increased to 51.7, 62.4, 47.10, 54.4, 55.3, 52.2, and
56.1 from VAD Days 1 to 7 (Fig. 2D).
The G value also increased to 6388.71, 7386.07, 6942.9,
8040.00, 8205.90, 9360.20, and 9122.90 kd/sc from VAD
Days 1 to 7 (Fig. 2E).
LY30 changed from 0.30% to 0.00% at VAD Day 1. At
VAD Days 2, 3, 4, 5, 6, and 7, the value was 0.48%, 0.20%,
1.60%, 3.50%, 3.80%, and 3.40%, respectively, for each
individual (Fig. 2F).
4. Discussion
VAD was beneficial for myocardial contractile improve-
ment and for obtaining heart chamber geometry.6e8 Mean-
while, the reversal of the downregulation of b receptor was
also observed in heart failure after device implantation;
therefore, inotropic agent sensitivity was also increased.9 The
VAD was designed with a centrifugal pump, incorporating anarterial and a venous cannula. The arterial cannula was placed
over the aorta, and the venous cannula was placed over the
apex of the heart or the left atrium. No supplemental oxygen
was provided (via an oxygenator); therefore, this device was
only suitable for normal lung gas exchange.
A potentially severe complication of ECMO is bleeding.
Exposure of blood to a rough surface without endothelium can
induce strong shear and hemolysis, especially in the oxygen-
ator. On the other hand, inflammatory response is also trig-
gered by coagulation, hemolysis, and thromboembosis, all of
which can injure vital organs.10 Hence, it is very important to
maintain the APTT at 1.3e1.6 times the normal range, and
ACT at approximately 160e180 seconds.
There are two types of VAD pumps: pulsatile and contin-
uous flow. The new flow pump is smaller in size, generates no
noise, and has demonstrated long-term durability. These
factors have allowed the patient to ambulate and return to
daily activities more easily. After VAD implantation, improved
Left ventricle ejection fraction (LVEF) and decreased Left
ventricle end-diastolic diameter (LVED) occurred more
rapidly than prior to VAD implantation.11
ECMOandVADwere both composed of a circulatory circuit,
and coagulation activities were also enhanced due to the tubing
system, which affected important components such as fibrino-
peptides, plasmin inhibitors, or protein C. However, there was
substantial variation in bleeding severity of those patients using
ECMO and VAD. Overall, there were fewer resulting blood
transfusions in patients using VAD than in those with ECMO.12
In the past, the most well-known application in hepatic and
cardiac surgery was TEG-guided transfusion of blood
components.13 Thereafter, TEG-guided transfusion became
less popular due to its long-term analysis and scarce repro-
ducibility. Gradually, the device was improved, as evidenced
by the newer, smaller size of the device, and a reduced time for
analysis. Similar to any surgery that had the potential for
massive blood loss, TEG was the standard choice for trans-
fusion of blood components. TEG is able to analyze from clot
formation through lysis and can pinpoint the insufficiency
within the coagulation cascade. Any insufficiency may result
from fibrinogen, platelet dysfunction, or anomalies in the
coagulation proteases. Minimizing these blood components,
while still ensuring their correct composition, is critical to
avoid potentially hazardous immune responses.14
Patients with ECMO are at a high risk for development of
coagulopathy. However, the cause of their bleeding can be
Fig. 2. TEG change from pre-VAD to VAD 7 day. A: R(min), B: K(min), C: MA(mm), D: Angle(Degree), E: G(kd/sc), F: LY30(%). *VAD implantation.
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prothrombin time (PT), APTT, and platelet counts, which has
prompted further analyses. TEG appears to be a better choice
to monitor clot development and overall stabilization. In the
ECMO group, the most common etiology of bleeding is
platelet dysfunction.15 The centrifugal pump of ECMO can
cause hemolysis, which will induce increased free hemoglobin
and decreased haptoglobin. The free red blood cells can cause
increased systemic vascular resistance, peripheral vascular
resistance, and platelet dysfunction, particularly 3 days after
ECMO being connected to the circuit. Alternatively, platelet
count may fall approximately 50% due to hemolysis. On
average, if the ECMO was used for approximately 1 week,
Packed red blood cells (PRBC) 0.5e1 U and platelet 0.5e2 U
are required daily. Then, platelet 1.06 U in venovenous (VV)ECMO and 1.57 U in venoarterial (VA) ECMO were used
daily.16 In our study, the mean platelet transfusion per day was
0.86e1.33 U, which is similar to the general mean
consumption of platelets. After shifting to VAD, the usage of
blood transfusion unit decreased significantly.
At first, TEG was used for liver transplantation. Twenty-five
years later, it was also used as an important part of cardiac
surgery due to coagulopathy in the heartelung machine. The
artificial heart was developed for the transitional phase of heart
transplantation. This device has certain advantages over the
ECMO, namely coagulopathy. In order to monitor the change
of coagulopathy, TEG was used for this examination.
The advantages of ECMO over an artificial heart (VAD)
include a simple insertion technique, avoidance of sternotomy
incision, and reduced cost. However, its disadvantages include
368 C.-Y. Huang et al. / Journal of the Chinese Medical Association 75 (2012) 363e369limited long-term support; hemolysis; patient immobilization;
increased chance of bleeding, stroke, and infection; limited
decompression of the LV; and an increased afterload. Bridge-
to-bridge is a concept for patients with cardiogenic shock.
Patients also suffered from comorbidities during ECMO
support. Consequently, to avoid a high risk of comorbidity,
implantable VAD should be considered for long-term
support.17
Successful coagulopathy associated with ECMO was
greater than that associated with VAD, because of the long
tubing system and oxygenator that accompanied the use of
ECMO. In addition, ECMO circuit often promotes the
formation of platelet aggregates and the formation of clots in
other organs. Hemolysis is related to the ECMO oxygenator
and nonendothelial surface of the circuit.18 Clots in the circuit
promote the activation of complement, white blood cells,
cofactors, and platelets.19 Consumptive coagulopathy was
found, including prothrombin activation fragment, fibrinogen,
platelet counts, and thrombineantithrombin Ⅲ complex,
especially during the first 48 hours.20
VAD presents similarities to an extracorporeal circuit and
encounters similar complications to those seen with the use of
ECMO. In the study of Steinlechner et al, it was demonstrated
that platelet dysfunction might be present in most patients with
VAD.21,22 Endothelial and coagulation systems were first
activated 2 hours into the postoperative period.20 The extrinsic
pathway (tissue factor) was accentuated due to endothelial
dysfunction when using VAD.23,24 However, coagulopathy in
VAD is less severe than in ECMO, due to the lack of an
oxygenator.
TEG offers a complete coagulation examination, including
cofactor function, platelet function, and clot lysis.15 This
examination is generally used in patients undergoing ECMO.
The ECMO tube and oxygenator contain rough surfaces, andTable 4
TEG in VAD Days 1e7.
VAD Day 1 VAD Day 2 VAD Day 3 VAD Day 4
R 12.10
(4.80e20.20)*
p ¼ 0.026
8.90
(3.40e10.60)*
p ¼ 0.026
11.50
(8.50e21.00)
9.50
(7.50e17.60
p ¼ 0.026
K 3.60
(1.70e15.30)*
p ¼ 0.026
3.00
(1.40e10.20)*
p ¼ 0001
5.50
(1.90e21.00)
3.70
(1.80e17.60
p ¼ 0.026
MA 54.10
(37.40e65.5)
58.40
(52.20e70.30)*
p ¼ 0.026
56.30
(26.20e65.90)
60.10
(38.90e70.2
Angle 51.70
(22.00e77.00)*
p ¼ 0.026
62.40
(52.70e71.70)*
p ¼ 0.001
47.10
(30.10e66.80)
54.4
(44.30e68.7
p ¼ .026
G 6388.70
(2983.00e9479.60)
7030.10
(5455.80e11,833.20)*
p ¼ 0.026
7800.10
(1771.80e9658.70)
8716.20
(3182.1e11
p ¼ 0.026
LY30 0.00
(e2.40 to 0.70)*
p ¼ 0.026
0.48
(e2.00 to 2.30)
0.20
(e0.10 to 19.20)
1.60
(e23.70 to
G ¼ clot strength; K ¼ kinetics time; LY30 ¼ estimated percent lysis in 30 minut
VAD ¼ ventricular assist device.
* Significant difference between pre-VAD (ECMO status) and VAD days.when the body touches the surface a coagulation response is
triggered. Implications of clot formation include the induction
of multiple embolisms and stroke. Heparin is often infused to
ameliorate potential coagulation problems. ACT was checked
as part of coagulation function; however, ACT could not
represent the complete status of coagulation. TEG is suitable
for monitoring coagulation.
Currently, many patients with end-stage heart disease are
seeking a heart transplant. Complications associated with
ECMO often occur more than 2 weeks after surgery in a post-
transplant setting. Consequently, an artificial heart (VAD) is
often suggested in part because VAD generally has fewer
coagulation complications than ECMO. TEG was applied for
coagulation change from ECMO to VAD.
A prolonged R value may indicate poor coagulation factor
trigger function. The current study showed that R value was
high in ECMO status and decreased after VAD insertion.
Significant differences were found between pre-VAD and
VAD insertion at VAD Days 1, 2, 4, and 7. The function of
coagulation factor may be improved after VAD. Similarly,
prolonged K value (the time of kinetics clot formation of
coagulation factor) is indicative of poor clot formation in the
beginning. Significant differences between pre-VAD and VAD
insertion were found at VAD Days 1, 2, 4, 6, and 7 (Table 4).
The angle indicates the rate of clot formation, and thus poor
angle may be indicative of slow clot formation. For example,
in the current study, the angle value was increased after VAD
insertion and resulted in a faster coagulation time. This result
may be explained by less consumption or normal platelet
function. MA represents the thickness of whole blood in the
ECMO tube. This procedure involved the interaction of the
coagulation factor and platelets. Poor MA may mean
a reduced platelet count or a poor platelet function. In our
study, a significant difference was noted at VAD Days 2, 6, andVAD Day 5 VAD Day 6 VAD Day 7
)*
9.10
(7.30e32.10)
10.90
(5.50e19.90)
9.40
(5.30e22.70)*
p ¼ 0.026
)*
2.70
(1.80e32.10)
3.40
(1.90e5.10)*
p ¼ 0.001
2.90
(1.70e5.80)*
p ¼0.001
0)
61.10
(49.40e68.70)
61.20
(43.00e73.1)*
p ¼ 0.001
64.90
(44.30e75.20)*
p ¼ 0.001
0)*
55.30
(26.80e66.40)*
p ¼ 0.026
52.20
(41.40e65.00)*
p ¼ 0.001
56.10
(46.40e68.80)*
p ¼ 0.001
,793.50)*
8585.20
(4888.80e10,976.00)
9108.40
(3774.30e13,577.60)*
p ¼ 0.001
8913.40
(3581.30e14,695.70)*
p ¼ 0.001
9.70)
3.50
(0.00e10.50)*
p ¼ 0.026
3.80
(0.00e48.00)
3.40
(0.98e17.00)*
p ¼ 0.001
es; MA ¼ maximal amplitude; R ¼ resting time; TEG ¼ thrombelastography;
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value indicates platelet dysfunction and thrombocytopenia.
Significant differences between pre-VAD and VAD insertion
were observed in patients with a VAD at 2, 4, 6, and 7 days
after procedure. The improvement in coagulation complica-
tions was considered to represent stable clot formation.
Stronger clot formation will prevent the spread of emboli
and limit hemorrhage tendency.
The ECMO setup induced severe coagulopathy arising
from TEG and many assessment parameters showed signifi-
cant difference from pre-ECMO status. In ECMO status, poor
coagulation factor and platelet function were induced due to
inflammatory response, and thrombocytopenia was found due
to massive rough surface consumption. This resulted in the
need for massive blood transfusion to restrict consumption of
coagulation factor and platelet, which often induced more
severe complications. After shifting from ECMO to VAD,
TEG appeared to promote normal coagulation. Meanwhile, the
strength of clot formation was suspected to be an important
factor for TEG improvement. VAD decreased bleeding risk
and maintain nearly normal coagulation function. Conse-
quently, it may be beneficial for patients to receive VAD for
recovery of heart function or to facilitate bridging to heart
transplantation.
In conclusion, coagulation will be significantly improved
after bridge to VAD is completed. This improvement in
coagulation complication from ECMO to VAD can be attrib-
uted to stable clot formation, thereby reducing the bleeding
complication significantly. The success rate of heart trans-
plants could be improved if bleeding was controlled by VAD.References
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